Chemomab Therapeutics (CMMB) Competitors $1.58 -0.06 (-3.60%) (As of 02:58 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMMB vs. ASRT, GBIO, PWUP, IVVD, PYRGF, GNTA, SLS, RLMD, GNLX, and FBLGShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Assertio (ASRT), Generation Bio (GBIO), PowerUp Acquisition (PWUP), Invivyd (IVVD), PyroGenesis Canada (PYRGF), Genenta Science (GNTA), SELLAS Life Sciences Group (SLS), Relmada Therapeutics (RLMD), Genelux (GNLX), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Assertio Generation Bio PowerUp Acquisition Invivyd PyroGenesis Canada Genenta Science SELLAS Life Sciences Group Relmada Therapeutics Genelux FibroBiologics Assertio (NASDAQ:ASRT) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends. Does the MarketBeat Community believe in ASRT or CMMB? Assertio received 90 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 64.29% of users gave Chemomab Therapeutics an outperform vote while only 59.67% of users gave Assertio an outperform vote. CompanyUnderperformOutperformAssertioOutperform Votes10859.67% Underperform Votes7340.33% Chemomab TherapeuticsOutperform Votes1864.29% Underperform Votes1035.71% Which has preferable valuation and earnings, ASRT or CMMB? Chemomab Therapeutics has lower revenue, but higher earnings than Assertio. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssertio$152.07M0.59-$331.94M-$0.73-1.30Chemomab TherapeuticsN/AN/A-$24.22M-$1.00-1.61 Is ASRT or CMMB more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Assertio-54.46% 3.79% 1.81% Chemomab Therapeutics N/A -101.70%-76.18% Do insiders & institutionals believe in ASRT or CMMB? 49.0% of Assertio shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 3.2% of Assertio shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ASRT or CMMB? Assertio has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Does the media refer more to ASRT or CMMB? In the previous week, Chemomab Therapeutics had 3 more articles in the media than Assertio. MarketBeat recorded 9 mentions for Chemomab Therapeutics and 6 mentions for Assertio. Assertio's average media sentiment score of 1.03 beat Chemomab Therapeutics' score of 0.41 indicating that Assertio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Chemomab Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ASRT or CMMB? Assertio presently has a consensus target price of $3.25, suggesting a potential upside of 243.19%. Chemomab Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 355.49%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryAssertio beats Chemomab Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.12M$6.50B$5.09B$8.81BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-1.615.4594.6014.18Price / SalesN/A373.721,217.5288.10Price / CashN/A52.5939.4936.27Price / Book1.4110.266.956.35Net Income-$24.22M$153.22M$118.83M$225.71M7 Day Performance-7.47%-1.74%-1.52%-0.32%1 Month Performance-1.23%-7.22%-3.39%1.76%1 Year Performance222.65%31.69%32.17%27.70% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.8811 of 5 stars$1.58-3.6%$7.33+363.8%+228.0%$22.70MN/A-1.5820ASRTAssertio3.2047 of 5 stars$0.95flat$3.25+242.1%-23.4%$90.71M$152.07M-1.3020Positive NewsGBIOGeneration Bio3.3756 of 5 stars$1.34-0.7%$7.50+459.7%+7.1%$89.50M$5.90M0.00150Gap UpPWUPPowerUp AcquisitionN/A$11.50flatN/AN/A$89.36MN/A0.00N/AIVVDInvivyd2.1459 of 5 stars$0.74-3.5%$7.52+913.8%-48.8%$88.69MN/A0.00100Analyst ForecastPYRGFPyroGenesis CanadaN/A$0.48-1.9%N/A+27.8%$87.70M$9.14M-8.0990News CoverageGNTAGenenta Science2.387 of 5 stars$4.70flat$25.00+431.9%-13.8%$85.96MN/A0.007News CoverageGap UpSLSSELLAS Life Sciences Group1.4284 of 5 stars$1.21-2.4%$3.00+147.9%+26.3%$85.16M$1M0.0016RLMDRelmada Therapeutics4.0947 of 5 stars$2.78-2.5%$7.50+169.8%-3.4%$83.87MN/A0.0010GNLXGenelux1.3484 of 5 stars$2.42-2.8%$18.25+654.1%-76.8%$83.59M$170,000.000.0010Gap UpFBLGFibroBiologics1.756 of 5 stars$2.41+7.6%$12.00+397.9%N/A$83.53MN/A0.0010 Related Companies and Tools Related Companies ASRT Competitors GBIO Competitors PWUP Competitors IVVD Competitors PYRGF Competitors GNTA Competitors SLS Competitors RLMD Competitors GNLX Competitors FBLG Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMMB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
